TECHNOPHAGE and SIMM, SHANGHAI INSTITUTE OF MATERIA MEDICA, a state-owned Institute administered and existing under the laws of the People’s Republic of China, have signed today a collaboration agreement for the joint development of a new pharmaceutical drug, leveraging the know-how and scientific complementarities of both entities in order to exploit new opportunities…

TECHNOPHAGE and UNIVERSITY OF MACAU, a University administered and existing under the laws of Macau Special Administrative Region, China, have signed today a Statement of Work relating to the development of new therapeutics directed at ageing-related diseases, including Parkinson’s disease.

A leading consortium of industrial partners has been awarded a grant by the Seventh Framework Program of the European Union for an innovative research and development project "TA101 GOCLIN: Clinical development of TA-101 for the treatment of rheumatoid arthritis" (#606352). The aim of this Project is to take TA101, a small domain antibody…

New patent granted to TechnoPhage/Lusomedicamenta Title: Antibacterial Phage, Phage Peptides and Methods of Use Thereof Office: United States Patent and Trademark Office Date: 22/10/2013 Patent no: US 8,563,504 B2